Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (29268)	2/19/2000 8:49:00 PM
From: Lee Walsh	Read Replies (1) \| Respond to of 150070

Here's another stock that might bear some watching. It also broke out of a range on Friday with 3-4 times average volume. It is not followed very closely that I could find...has just a very few posts on RB, and I don't believe any internet site has picked it up. DBOT -- Demegen Demegen, Inc. is a research and development company that designs novel peptides and genes to improve the health of humans, animals, and plants. Building upon interconnected technology platforms, the Company has both pharmaceutical and agricultural products in development. The medical applications include preventing or treating cancers and infectious diseases. The agricultural applications include plants that have genetically enhanced fungal and bacterial disease resistance and plants with improved protein quality and quantity. Demegen's website is demegen.com. Common Shares Outstanding: 26,361,899 Preferred Shares Outstanding: 4,444,444 Float (approximate): 16,062,794 shares 30 Day Avg. Daily Trading Vol.: 93,000 shares Interesting News: Thursday January 6, 9:43 am Eastern Time Company Press Release SOURCE: Demegen, Inc. Demegen Awarded U.S. Patent for Method of Wound Healing PITTSBURGH, Jan. 6 /PRNewswire/ -- Demegen, Inc. (OTC Bulletin Board: DBOT - news) announces that it was awarded Patent No. 6,001,805 from the United States Patent and Trademark Office for promoting healing of burn or surgical wounds with amphipathic peptides by stimulating growth of dermal tissue. The invention is entitled, ``Method of Enhancing Wound Healing by Stimulating Fibroblast and Keratinocyte Growth In Vivo, Utilizing Amphipathic Peptides.' This patent is Demegen's seventh United States patent and the second that specifically addresses wound healing. The use of topical antimicrobial agents has been an important adjunct in the prevention and treatment of burn wound infections. However, the most common agents can significantly inhibit wound healing. Furthermore, the emergence of multi-drug resistant organisms has become an increasingly important problem in the management of major surgical infections, including burn wounds. Hence, there is a significant need for new antimicrobial products to prevent and treat hospital incurred infections. Demegen compounds have demonstrated substantial activity against clinically relevant strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus without being cytotoxic to fibroblasts or keratinocytes. Demegen is currently completing pre-clinical evaluation of a product to prevent and treat infected wounds in preparation for human clinical trials. Demegen, Inc. is a research and development company that designs novel peptides and genes to improve the health of humans, animals, and plants. Building upon interconnected technology platforms, the Company has both pharmaceutical and agricultural products in development. The medical applications include preventing or treating cancers and infectious diseases. The agricultural applications include plants that have genetically enhanced fungal and bacterial disease resistance and plants with improved protein quality and quantity. Demegen's website is demegen.com. Forward-looking statements in this release are made pursuant to the ``safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, results of research and development, the U.S. Food and Drug Administration and other regulatory agencies, increased competition, product development and commercialization, and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission. Contact: Richard Ekstrom, President of Demegen, 412-241-2150, or E-mail, info@demegen.com www.demegen.com